Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Ensuring Compliance with Schedule Y Clinical Requirements – V 2.0

Posted on By

BA-BE Studies: SOP for Ensuring Compliance with Schedule Y Clinical Requirements – V 2.0

Standard Operating Procedure for Ensuring Compliance with Schedule Y Clinical Requirements in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/111/2025
Supersedes SOP/BA-BE/111/2022
Page No. Page 1 of 9
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To define a standardized procedure for ensuring full compliance with the provisions of Schedule Y of the Drugs and Cosmetics Rules, 1945, during the planning and conduct of Bioavailability/Bioequivalence (BA/BE) studies in India.

2. Scope

This SOP applies to all staff involved in clinical trial operations, regulatory affairs, documentation, monitoring, and quality assurance of BA/BE studies regulated under Schedule Y in India.

3. Responsibilities

  • Regulatory Affairs Manager: Ensures that all study submissions are in accordance with Schedule Y requirements.
  • Principal Investigator: Complies with responsibilities outlined under Investigator obligations of Schedule Y.
  • QA Officer: Audits processes and documents for compliance with Schedule Y.
  • Clinical Research Coordinator: Maintains regulatory essential documents and supports audit readiness.
See also  BA-BE Studies: SOP for Pre-Study Kickoff Meeting Conduct - V 2.0

4. Accountability

The Head of Regulatory Affairs is accountable for ensuring that all BA/BE studies conducted are in full compliance with Schedule Y requirements from study initiation to archival.

5. Procedure

5.1 Review of Schedule Y Provisions

  1. All study staff must be trained on the current version of Schedule Y.
  2. Maintain a controlled copy of Schedule Y in the Quality and Regulatory Documentation Library.

5.2 Clinical Trial Authorization (CTA)

  1. Ensure BE protocol is filed to CDSCO along with Form 44 and requisite fees.
  2. Attach Investigator Undertaking (Form 2), Institutional Ethics Committee (IEC) approval, and reference product labeling.

5.3 Ethics Committee Compliance

  1. Ensure study protocol, informed consent forms, and any advertisement material are approved by IEC before subject enrollment.
  2. All SAE reporting must follow 24-hour and 14-day reporting timelines as per Schedule Y.

5.4 Volunteer Protection and Consent

  1. Ensure audio-visual informed consent recording where applicable.
  2. Provide complete explanation of risks, study objectives, and rights of subjects as per ethical guidelines.
See also  BA-BE Studies: SOP for Developing Study Synopsis for Ethics Submission - V 2.0

5.5 Documentation Compliance

  1. Maintain Investigator Site File (ISF) as per Schedule Y structure.
  2. Verify availability of:
    • Form 44 approval
    • IEC approval letters
    • CRFs and subject logs

5.6 Study Monitoring and Audits

  1. Schedule periodic monitoring visits by QA and sponsor monitors.
  2. Ensure documentation of protocol deviations, SAEs, consent deviations, and other observations.

5.7 Reporting and Archival

  1. Compile Clinical Study Report (CSR) in Schedule Y format for submission to CDSCO.
  2. Archive all records for at least 5 years post study completion or as directed by sponsor.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • CDSCO: Central Drugs Standard Control Organization
  • CSR: Clinical Study Report
  • QA: Quality Assurance
  • IEC: Institutional Ethics Committee

7. Documents

  1. Schedule Y Reference Copy – Annexure-1
  2. Form 44 Submission Checklist – Annexure-2
  3. IEC Approval Tracking Sheet – Annexure-3
  4. SAE Reporting Log – Annexure-4
  5. Archival Checklist – Annexure-5

8. References

  • Schedule Y – Drugs and Cosmetics Rules, 1945 (Amended 2005)
  • ICH E6(R2) – Good Clinical Practice
  • Indian GCP Guidelines 2001
See also  BA-BE Studies: SOP for Blinding and Unblinding Protocols in BA/BE Studies - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Schedule Y Reference Copy

Controlled version of Schedule Y guidelines – latest amendment dated 2023.

Annexure-2: Form 44 Submission Checklist

Document Available Remarks
Study Protocol Yes
Form 2 – Investigator Undertaking Yes

Annexure-3: IEC Approval Tracking Sheet

Protocol ID IEC Approval Date Version Renewal Due
BE-111-2025 01/03/2025 1.0 01/03/2026

Annexure-4: SAE Reporting Log

Volunteer ID Event Date Reported to IEC Reported to CDSCO
VOL-111-003 05/04/2025 06/04/2025 08/04/2025

Annexure-5: Archival Checklist

Document Type Archived Location
ISF Yes Archive Room Shelf A2

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial SOP release Regulatory Compliance QA Head
17/04/2025 2.0 Expanded annexures and tracking logs added Schedule Y Update QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for Use and Maintenance of Biosafety Cabinets – V 2.0
Next Post: Analytical Method Development: Handling of AMD Method Notebooks – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version